Source comparison
Comparison: Sermorelin Safety Studies vs Other Growth Hormone Secretagogues
Published human safety trials >6 months Yes. JCEM 1995, 102 adults, 6 months Limited. Small cohorts <30 subjects No. Longest published trial is 90 days Yes. Phase II trials up to 2 years Sermorelin has the most robust long-term human data; MK-677 has longer tr
This comparison does not assign a generated winner or score.
- Published human safety trials >6 months
- Yes. JCEM 1995, 102 adults, 6 months
- Limited. Small cohorts <30 subjects
- No. Longest published trial is 90 days
- Yes. Phase II trials up to 2 years
- Sermorelin has the most robust long-term human data; MK-677 has longer trials but oral bioavailability introduces GI and appetite variables
- FDA regulatory status
- Approved 1997 (diagnostic use)
- Not FDA-approved
- Not FDA-approved (investigated as ghrelin receptor agonist)
- Only sermorelin has FDA approval requiring safety documentation
- Adverse event rate at therapeutic dose
- <3% (primarily injection site reactions)
- 3–8% (mild headache, water retention)
- Unknown. Insufficient data
- 8–15% (increased appetite, transient edema)
- Sermorelin shows lowest documented adverse event rate in controlled trials
- Mechanism specificity
- Selective GHRH receptor agonist
- Selective growth hormone secretagogue receptor agonist
- Modified GHRH with extended half-life
- Non-selective ghrelin receptor agonist (affects appetite and cortisol)
- Sermorelin's selectivity limits off-target effects; MK-677's ghrelin activity increases hunger and cortisol in some subjects
- Half-life / dosing frequency
- ~10 minutes; daily dosing required
- ~2 hours; daily or twice-daily
- ~6–8 days (with DAC modification); weekly dosing
- ~4–6 hours; daily oral dosing
- Short half-life limits accumulation risk but requires consistent administration
- Sermorelin safety studies demonstrate a narrower adverse event profile than comparators, largely due to its selectivity for GHRH receptors without cross-reactivity to ghrelin or other pathways. CJC-1295's modified structure extends half-life but lacks long-term human safety data. The longest published trial is 90 days in 20 subjects.